Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity

Science China Life Sciences

Volumn 57, Issue 10, 2014, Pages 1011-1017

  Shao, TengFei ^a   Zheng, YuanTing ^a   Zhao, Bei ^a   Li, Tao ^a   Cheng, KeGuang ^b   Cai, WeiMin ^a  

^a FUDAN UNIVERSITY   (China)

^b GUANGXI NORMAL UNIVERSITY   (China)

Author keywords

anti cancer drug; cancer chemotherapeutic; K ras; mutation; pancreas; plasmids

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GREEN FLUORESCENT PROTEIN; QUINAZOLINE DERIVATIVE; RAS PROTEIN; RECOMBINANT PROTEIN;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; ONCOGENE RAS; PANCREAS; PANCREAS TUMOR; PLASMID; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GREEN FLUORESCENT PROTEINS; HUMANS; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; PLASMIDS; QUINAZOLINES; RAS PROTEINS; RECOMBINANT PROTEINS;

EID: 84920378631     PISSN: 16747305     EISSN: 18691889     Source Type: Journal    
DOI: 10.1007/s11427-014-4724-0     Document Type: Article

References (22)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 1988, 53: 549–554
2. Hanlon L, Avila JL, Demarest RM, Troutman S, Allen M, Ratti F, Rustgi AK, Stanger BZ, Radtke F, Adsay V, Long F, Capobianco AJ, Kissil JL. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res, 2010, 70: 4280–4286
3. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 2001, 410: 1111–1116
4. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 2010, 140: 209–221
5. Martin TD, Samuel JC, Routh ED, Der CJ, Yeh JJ. Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res, 2011, 71: 206–215
6. Shen L, Nishioka T, Guo J, Chen C. Geminin functions downstream of p53 in K-ras-induced gene amplification of dihydrofolate reductase. Cancer Res, 2012, 72: 6153–6162
7. Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for K-RAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res, 2011, 71: 445–453
8. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA, 2008, 105: 2652–2657
9. Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A, Raymond E. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev, 2013, 32: 147–162
10. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther, 2009, 16: 554–561
11. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol, 2007, 25: 5240–5247
12. Capelletti M, Wang XF, Gu L, Graziano SL, Kratzke RA, Strauss GM, Maddaus M, Green MR, Vokes EE, Janne PA. Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. J Clin Oncol, 2010, 28: 7008
13. Pickard M, Sherrington P, Brett M, Green B, Howelevans A, Smith D, Poston G, Kinsella A. Mutation in the K-ras gene at codon 12 does not correlate with disease progression in colorectal carcinoma patients treated with 5-FU/folinic acid biomodulated chemotherapy. Int J Oncol, 1996, 9: 1301–1306
14. Rosty C, Chazal M, Etienne MC, Letoublon C, Bourgeon A, Delpero JR, Pezet D, Beaune P, Laurent-Puig P, Milano G. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer, 2001, 95: 162–167
15. Xiao J, Chen LW, Chen JX, Lin HY, Huang B. Construction of a recombinant eukaryotic expression plasmid containing human PDLIM2 gene and its biological activity. Plasmid, 2011, 66: 106–111
16. Toulany M, Schickfluss TA, Eicheler W, Kehlbach R, Schittek B, Rodemann HP. Impact of oncogenic K-RAS on YB-1 phosphor-ylation induced by ionizing radiation. Breast Cancer Res, 2011, 13: R28
17. Minjgee M, Toulany M, Kehlbach R, Giehl K, Rodemann HP. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys, 2011, 81: 1506–1514
18. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res, 2007, 67: 2098–2106
19. Banerjee J, Al-Wadei HA, Schuller HM. Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts. Eur J Cancer, 2013, 49: 1152–1158
20. Liu S, Wang J, Niu W, Liu E, Wang J, Peng C, Lin P, Wang B, Khan AQ, Gao H, Liang B, Shahbaz M, Niu J. The beta6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. Cancer Lett, 2013, 328: 325–334
21. Jeong EK, Lee SY, Jeon HM, Ju MK, Kim CH, Kang HS. Role of extracellular signal-regulated kinase (ERK)1/2 in multicellular resistance to docetaxel in MCF-7 cells. Int J Oncol, 2010, 37: 655–661
22. Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, Scanni A, Broggini M. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol, 2011, 22: 235–237